Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
The Global, Regional, and National Burden of Inflammatory Bowel Disease in 195 Countries and Territories, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017 Publisher Pubmed



Alatab S5 ; Sepanlou SG5, 8 ; Ikuta K11, 12 ; Vahedi H5 ; Bisignano C12 ; Safiri S13, 14 ; Sadeghi A5 ; Nixon MR12 ; Abdoli A16 ; Abolhassani H6, 17 ; Alipour V19, 20 ; Almadi MAH22, 23 ; Almasihashiani A18 ; Anushiravani A4 Show All Authors
Authors
  1. Alatab S5
  2. Sepanlou SG5, 8
  3. Ikuta K11, 12
  4. Vahedi H5
  5. Bisignano C12
  6. Safiri S13, 14
  7. Sadeghi A5
  8. Nixon MR12
  9. Abdoli A16
  10. Abolhassani H6, 17
  11. Alipour V19, 20
  12. Almadi MAH22, 23
  13. Almasihashiani A18
  14. Anushiravani A4
  15. Arabloo J21
  16. Atique S24, 25
  17. Awasthi A26, 27
  18. Badawi A28, 29
  19. Baig AAA30, 31
  20. Bhala N32, 33
  21. Bijani A34
  22. Biondi A35
  23. Borzi AM36
  24. Burke KE37
  25. Carvalho F38, 39
  26. Daryani A40
  27. Dubey M41
  28. Eftekhari A15, 43
  29. Fernandes E45
  30. Fernandes JC44
  31. Fischer F46
  32. Hajmirzaian A3, 49
  33. Hajmirzaian A3, 49
  34. Hasanzadeh A2, 42
  35. Hashemian M51, 52
  36. Hay SI12
  37. Hoang CL53
  38. Househ M54, 55
  39. Ilesanmi OS56
  40. Balalami NJ57
  41. James SL12
  42. Kengne AP58, 59
  43. Malekzadeh MM5
  44. Merat S5
  45. Meretoja TJ60, 61
  46. Mestrovic T62, 63
  47. Mirrakhimov EM64, 65
  48. Mirzaei H1, 66
  49. Mohammad KA67, 68
  50. Mokdad AH10, 12
  51. Monasta L69
  52. Negoi I70, 71
  53. Nguyen TH53
  54. Nguyen CT72
  55. Pourshams A5
  56. Poustchi H5
  57. Rabiee M73
  58. Rabiee N74
  59. Ramezanzadeh K48
  60. Rawaf DL77, 78
  61. Rawaf S75, 79
  62. Rezaei N6, 80
  63. Robinson SR81
  64. Ronfani L69
  65. Saxena S76
  66. Sepehrimanesh M82, 83
  67. Shaikh MA84
  68. Sharafi Z85
  69. Sharif M86, 87
  70. Siabani S88, 89
  71. Sima AR5, 7
  72. Singh JA90
  73. Soheili A91, 92
  74. Sotoudehmanesh R5
  75. Suleria HAR93
  76. Tesfay BE94
  77. Tran B95
  78. Tsoi D12
  79. Vacante M35
  80. Wondmieneh AB96, 97
  81. Zarghi A47
  82. Zhang ZJ98
  83. Dirac M12
  84. Malekzadeh R5, 9
  85. Naghavi M10, 12

Source: The Lancet Gastroenterology and Hepatology Published:2020


Abstract

Background: The burden of inflammatory bowel disease (IBD) is rising globally, with substantial variation in levels and trends of disease in different countries and regions. Understanding these geographical differences is crucial for formulating effective strategies for preventing and treating IBD. We report the prevalence, mortality, and overall burden of IBD in 195 countries and territories between 1990 and 2017, based on data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017. Methods: We modelled mortality due to IBD using a standard Cause of Death Ensemble model including data mainly from vital registrations. To estimate the non-fatal burden, we used data presented in primary studies, hospital discharges, and claims data, and used DisMod-MR 2.1, a Bayesian meta-regression tool, to ensure consistency between measures. Mortality, prevalence, years of life lost (YLLs) due to premature death, years lived with disability (YLDs), and disability-adjusted life-years (DALYs) were estimated. All of the estimates were reported as numbers and rates per 100 000 population, with 95% uncertainty intervals (UI). Findings: In 2017, there were 6·8 million (95% UI 6·4–7·3) cases of IBD globally. The age-standardised prevalence rate increased from 79·5 (75·9–83·5) per 100 000 population in 1990 to 84·3 (79·2–89·9) per 100 000 population in 2017. The age-standardised death rate decreased from 0·61 (0·55–0·69) per 100 000 population in 1990 to 0·51 (0·42–0·54) per 100 000 population in 2017. At the GBD regional level, the highest age-standardised prevalence rate in 2017 occurred in high-income North America (422·0 [398·7–446·1] per 100 000) and the lowest age-standardised prevalence rates were observed in the Caribbean (6·7 [6·3–7·2] per 100 000 population). High Socio-demographic Index (SDI) locations had the highest age-standardised prevalence rate, while low SDI regions had the lowest age-standardised prevalence rate. At the national level, the USA had the highest age-standardised prevalence rate (464·5 [438·6–490·9] per 100 000 population), followed by the UK (449·6 [420·6–481·6] per 100 000). Vanuatu had the highest age-standardised death rate in 2017 (1·8 [0·8–3·2] per 100 000 population) and Singapore had the lowest (0·08 [0·06–0·14] per 100 000 population). The total YLDs attributed to IBD almost doubled over the study period, from 0·56 million (0·39–0·77) in 1990 to 1·02 million (0·71–1·38) in 2017. The age-standardised rate of DALYs decreased from 26·5 (21·0–33·0) per 100 000 population in 1990 to 23·2 (19·1–27·8) per 100 000 population in 2017. Interpretation: The prevalence of IBD increased substantially in many regions from 1990 to 2017, which might pose a substantial social and economic burden on governments and health systems in the coming years. Our findings can be useful for policy makers developing strategies to tackle IBD, including the education of specialised personnel to address the burden of this complex disease. Funding: Bill & Melinda Gates Foundation. © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
Other Related Docs